Daiichi Sankyo Pharmaceuticals

Daiichi Sankyo is a leading global pharmaceutical company based in Japan. It was formed in 2005 through the merger of two historic Japanese pharmaceutical firms, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. The brand focuses on developing innovative therapies across various medical fields, particularly in oncology and cardiovascular healthcare.

While headquartered in Tokyo, Daiichi Sankyo maintains a massive global footprint with manufacturing facilities and research centers located in Japan, the United States, Europe, and Asia. This distributed manufacturing network allows the company to supply critical medications to global markets efficiently while complying with local health regulations.

The ultimate owner is the publicly traded Daiichi Sankyo Company, Limited. As a primary global innovator, the company operates many regional subsidiaries to manage local distribution and clinical trials, ensuring their pharmaceutical advancements reach patients worldwide under a unified corporate strategy.